Protagonist Therapeutics, Inc. (PTGX) Stock

Protagonist Therapeutics, Inc. (PTGX) is a Healthcare stock trading at $112.59 (as of 2026-06-18), with a market capitalization of $6.40B and a trailing P/E of -55.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Protagonist Therapeutics, Inc. develops peptide-based therapeutic drugs for hematology and blood disorders, and for inflammatory and immunomodulatory diseases. Its pipeline includes rusfertide (PTG-300), an injectable hepcidin mimetic, and PN-943 and PN-235, oral peptide candidates, with clinical development in multiple Phase II indications.

Valuation — source: SEC EDGAR (first-party)
Price	$112.59
Market Cap	$6.40B
P/E Ratio	-55.0
EV / EBITDA	-44.0
Price / Book	9.77
Price / Sales	86.45
DCF Value (model)	$16.98
DCF Upside vs Price	-84.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$46.02M
Net Margin	-282.8%
Return on Equity	-17.5%
Current Ratio	17.76
Revenue Growth (YoY)	99.0%
EPS Growth (YoY)	-131.6%
FCF Growth (YoY)	-139.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	79.86 (safe)

Valuation vs Sector & Industry
Stock P/E	-55.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-362.4%
vs Industry	-418.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($1.03B)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dinesh V. Patel
Employees	124
Country	US
IPO Date	2016-08-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.